Dr Maria Rosaria Abbattista

Biography

Research interests

Selected publications and creative works (Research Outputs)

  • Stabbing, L. A., Kavianinia, I., Abbattista, M. R., Harris, P. W. R., Smaill, J. B., Patterson, A. V., & Brimble, M. A. (2019). Synthesis and antiproliferative activity of culicinin D analogues containing simplified AHMOD-based residues. European Journal of Medicinal Chemistry, 177, 235-246. 10.1016/j.ejmech.2019.05.052
    Other University of Auckland co-authors: Iman Kavianinia, Jeffrey Smaill, Adam Patterson, Margaret Brimble, Louise Stubbing
  • Niemans, R., Yaromina, A., Theys, J., Ashoorzadeh, A., Anderson, R., Bull, M., ... Mowday, A. (2017). Hypoxic cell killing by SN36506, a novel hypoxia-activated prodrug. Paper presented at Estro 36, Vienna, Austria. 5 May - 9 May 2017. Radiotherapy & Oncology. 10.1016/S0167-8140(17)31031-9
    Other University of Auckland co-authors: Amir Ashoorzadeh, Bob Anderson, Matthew Bull, Annie Hsu, Adam Patterson, Jeffrey Smaill
  • Guise, C., Abbattista, M., Mowday, A., Ashoorzadeh, A., Bull, M., Silva, S., ... Theys, J. (2017). SN36506: A rationally designed second generation analogue of PR-104 selected for clinical evaluation. Paper presented at 15th International Tumour Microenvironment Workshop, Miami, FL, USA. 27 April - 29 April 2017.
    Other University of Auckland co-authors: Amir Ashoorzadeh, Bob Anderson, Jack Flanagan, Kevin Hicks, Jeffrey Smaill, Adam Patterson, Matthew Bull
  • Mowday, A., Ashoorzadeh, A., Williams, E., Copp, J., Silva, S., Bull, M., ... Guise, C. (2016). Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy. Biochemical Pharmacology, 116, 176-187. 10.1016/j.bcp.2016.07.015
    URL: http://hdl.handle.net/2292/30209
    Other University of Auckland co-authors: Jack Flanagan, Adam Patterson, Bob Anderson, Jeffrey Smaill, Amir Ashoorzadeh, Matthew Bull
  • Silva, S., Jackson, V., Guise, C., Abbattista, M., Bull, M., Grey, A., ... Pearce, T. (2015). Preclinical efficacy of tarloxotinib bromide (TH­4000), a hypoxia­activated EGFR/HER2 inhibitor: Rationale for clinical evaluation in EGFR mutant, T790M-­negative NSCLC following progression on EGFRTKI therapy. Paper presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts. 5 November - 9 November 2015. Molecular Cancer Therapeutics. (pp. 2).
    Other University of Auckland co-authors: Gus Grey, Bob Anderson, Amir Ashoorzadeh, Adam Patterson, Jeffrey Smaill, Matthew Bull, Victoria Jackson-Patel
  • Patterson, A., Silva, S., Jackson, V., Guise, C., Abbattista, M. R., Bull, M., ... Jung, D. (2015). The hypoxia-activated EGFR-TKI TH-4000: Preclinical profile and ongoing clinical studies in NSCLC, SCCHN, and SCCS. Paper presented at 14th International Tumor Microenvironment Workshop: Hypoxia, Angiogensis and Vasculature, Vancouver, Canada. 27 August - 29 August 2015.
    URL: http://hdl.handle.net/2292/27747
    Other University of Auckland co-authors: Adam Patterson, Amir Ashoorzadeh, Bob Anderson, Jeffrey Smaill, Matthew Bull, Gus Grey
  • Patterson, A. V., Silva, S., Guise, C., Abbattista, M., Bull, M., Hsu, H.-L., ... Ashoorzadeh, A. (2015). The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial. Paper presented at 106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, Pennsylvania, USA. 18 April - 22 April 2015. Cancer Research. (pp. 2). 10.1158/1538-7445.AM2015-5358
    Other University of Auckland co-authors: Gus Grey, Adam Patterson, Amir Ashoorzadeh, Bob Anderson, Jeffrey Smaill, Matthew Bull
  • Patterson, A. V., Silva, S., Guise, C., Bull, M., Abbattista, M., Hsu, A., ... Smaill, J. B. (2015). TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC. Paper presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago, Illinois, USA. 29 May - 2 June 2015. Journal of Clinical Oncology. (pp. 1).
    Other University of Auckland co-authors: Jeffrey Smaill, Adam Patterson, Matthew Bull

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 0, Room 005
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand